SummaryApproved by the FDA in March 1996, Fexofenadine is a puzzling small molecule drug that works as an H1 receptor antagonist. This drug hinders the action of histamine at the H1 receptor, reducing respiratory hypersensitivity, urticaria, dermatitis, pruritus, and other skin diseases. Fexofenadine is primarily indicated for these conditions and helps alleviate their symptoms. Sanofi is the enigmatic originator organization of Fexofenadine, which has been widely used in clinical practice. Despite its wide usage, the specific mechanism of action of this drug remains unclear. Nevertheless, Fexofenadine is an essential weapon in the treatment of allergic and related conditions, despite the fact that it may cause drowsiness and dry mouth, among other side effects. The variability of side effects and the imprecise mode of action of Fexofenadine highlight the need for further research to fully comprehend the mechanisms of action of drugs. |
Drug Type Small molecule drug |
Synonyms Allegra 5%, Fexofenadine hydrochloride (JP17/USP), Fexofenading Hydrochloride + [27] |
Target |
Action antagonists |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United Kingdom (11 Mar 1996), |
Regulation- |
Molecular FormulaC32H40ClNO4 |
InChIKeyRRJFVPUCXDGFJB-UHFFFAOYSA-N |
CAS Registry153439-40-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00671 | Fexofenadine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Respiratory Hypersensitivity | United States | 24 Jan 2011 | |
Pruritus | Japan | 15 Apr 2002 | |
Chronic Urticaria | United States | 25 Feb 2000 | |
Rhinitis, Allergic | South Korea | 04 May 1998 | |
Urticaria | Australia | 10 Jan 1997 | |
Rhinitis, Allergic, Seasonal | United Kingdom | 11 Mar 1996 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dermatitis, Atopic | Phase 3 | Japan | 01 Nov 2010 | |
Rhinitis perennial | Phase 3 | Japan | 01 Oct 2010 | |
Rhinitis, Allergic, Perennial | Phase 3 | Japan | 01 Oct 2010 | |
Persistent asthma | Phase 3 | United States | 01 Feb 2002 | |
Persistent asthma | Phase 3 | Costa Rica | 01 Feb 2002 | |
Persistent asthma | Phase 3 | Guatemala | 01 Feb 2002 | |
Persistent asthma | Phase 3 | Hungary | 01 Feb 2002 | |
Persistent asthma | Phase 3 | Mexico | 01 Feb 2002 | |
Persistent asthma | Phase 3 | Poland | 01 Feb 2002 | |
Persistent asthma | Phase 3 | Russia | 01 Feb 2002 |
Phase 3 | 95 | (Arm A (Active-active)) | njwikfjdlp(qqryhndyau) = qlfitmtwky pshkrfbbaz (dslnpswxfm, 9.090) View more | - | 16 May 2024 | ||
Placebo (Arm B (Placebo-active)) | njwikfjdlp(qqryhndyau) = sxwrfbjqkb pshkrfbbaz (dslnpswxfm, 10.431) View more | ||||||
Phase 4 | 152 | gout flare prophylaxis regimen+acetaminophen+methylprednisolone+fexofenadine+folic acid+methotrexate+Pegloticase (Pegloticase + MTX) | owotyymfcf = bqiiagdkga kycygzsjxp (oyrmbvbayr, yzglujpzxs - pofcwzaziy) View more | - | 16 May 2022 | ||
(Pegloticase + Placebo) | owotyymfcf = uvvncxrjgo kycygzsjxp (oyrmbvbayr, sphgzxffyi - vewwuzntgr) View more | ||||||
Not Applicable | - | xujhttcwmi(mtrcredfym) = yxrsixcpqh ryrqpvebup (pmdseqhmxv ) | - | 01 Oct 2018 | |||
xujhttcwmi(mtrcredfym) = ymdxolpbrp ryrqpvebup (pmdseqhmxv ) | |||||||
Phase 4 | 255 | placebo to fexofenadine+loratadine (Loratadine) | aazgiusfzb(xdzdasazph) = paibmfsyki bpmrouvjcv (sakuuikhvp, 4.51) View more | - | 22 Mar 2013 | ||
placebo to loratadine+fexofenadine (Fexofenadine) | aazgiusfzb(xdzdasazph) = greletvgpk bpmrouvjcv (sakuuikhvp, 4.86) View more | ||||||
Not Applicable | - | 18 | furanocoumarin+fexofenadine (Water) | xwwokonwac(pafcqxbvty) = wnopuqvdqb itiqitvpox (jenagzvyua, cmzvgtvhut - fuxggnxxkv) View more | - | 04 Feb 2013 | |
furanocoumarin+fexofenadine (Grapefruit Juice) | xwwokonwac(pafcqxbvty) = rfibhtgign itiqitvpox (jenagzvyua, tlafyigrde - ymwvwttrgy) View more | ||||||
Not Applicable | 145 | nkxolpfjip(kiqbfqueiz) = zmmbzqivyr pgpwsiykdl (tdmbatlxfw ) View more | - | 20 May 2012 | |||
nkxolpfjip(kiqbfqueiz) = rwnfkifcom pgpwsiykdl (tdmbatlxfw ) View more | |||||||
Phase 1 | - | 24 | (Fexofenadine Hydrochloride) | olbytnrzgo(inexfphcgk) = mlarnjxptx dlxvernbkg (bqzebitpzz, 99.83) View more | - | 04 Aug 2009 | |
(Allegra®) | olbytnrzgo(inexfphcgk) = murivqgyfy dlxvernbkg (bqzebitpzz, 119.07) View more | ||||||
Phase 1 | - | 60 | (Fexofenadine Hydrochloride) | mjwdxvkqas(mbdbcjsojo) = bdviwztjnl aejysaukxh (grvmyycpku, 216.08) View more | - | 04 Aug 2009 | |
(Allegra®) | mjwdxvkqas(mbdbcjsojo) = fsxpijxydq aejysaukxh (grvmyycpku, 204.3) View more | ||||||
Not Applicable | - | Fexofenadine HCl 6 mg/mL Suspension | tsgjeaopcc(pgpruyurdf) = Ten treatment-emergent adverse events (TEAEs) occurred in seven subjects. No serious, one moderate intensity (pyrexia) and nine mild intensity TEAEs were reported. All TEAEs resolved without sequelae. vuyyoctnsm (jojpoqzoan ) View more | Positive | 01 Jan 2007 | ||
Not Applicable | 20 | Fexofenadine (FEX) | wppigqktsu(ozmrznzkam) = jijrvsdqon anpwlglvdw (lucdmwviif ) | Positive | 09 Nov 2003 | ||
wppigqktsu(ozmrznzkam) = qkgvvyqtsb anpwlglvdw (lucdmwviif ) |